Review recaps SURMOUNT-OSA tirzepatide cuts apnea-hypopnea index by up to 23.8 events hourly

The wire

1. 01Two 52-week placebo-controlled phase 3 trials enrolled 469 adults with obesity and an apnea-hypopnea index of at least 15 events per hour, with and without positive airway pressure.
2. 02Tirzepatide reduced AHI by an estimated 20.0 and 23.8 events per hour versus placebo, alongside drops in hypoxic burden, weight, systolic blood pressure and hs-CRP.
3. 03This is a narrative review for cardiologists, not new data; cardiovascular event outcomes with tirzepatide in sleep apnea remain unestablished.

From the source

Tirzepatide for Obstructive Sleep Apnea: Trial Evidence, Cardiometabolic Effects, and Implications for Cardiovascular Practice

Cardiology in review · 2026 Oct 20 · Arslan FS, Ahmad R, Frishman WH et al.